Jeeva Informatics

Executive Summary

Jeeva Informatics offers an AI-assisted unified eClinical platform designed to simplify and automate clinical trial workflows, targeting emerging biopharma, MedTech sponsors, CROs, and research sites. By reducing manual burdens, the platform aims to accelerate study timelines and improve patient access and engagement. Founded in 2018 and based in San Francisco, the company operates in the growing digital health and AI sectors, addressing inefficiencies that cost the clinical trial industry billions annually. Its focus on smaller sponsors and sites positions it to capture a niche underserved by larger electronic data capture (EDC) vendors, though it faces competition from established players and other startups. Currently at Phase 1 stage (likely pre-revenue or early commercialization), Jeeva has not disclosed funding or valuation, suggesting it may be bootstrapped or in early fundraising. The company's success hinges on its ability to differentiate through AI capabilities, secure pilot customers, and prove ROI in a risk-averse industry. Key risks include long sales cycles, regulatory uncertainties, and the need for integration with existing systems. If Jeeva can demonstrate tangible efficiency gains, it has potential to scale within the fragmented eClinical market, but it remains a high-risk, early-stage opportunity.

Upcoming Catalysts (preview)

• H2 2026Series A Funding Announcement60% success
• Q3 2026Major Partnership with a Mid-Sized CRO35% success
• Q4 2026New AI-Powered Module Launch (e.g., Patient Recruitment)50% success